# REZILIENT1 (zipalertinib): what clinicians are saying

> 129 statements from 58 sources (4 videos, 52 posts, 2 papers), 58 of them from 21 confirmed clinicians, each linked to its source. Commentary checked Nov 10, 2026.

## Report

- Trial: A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
- NCT ID: NCT04036682
- Registry: https://clinicaltrials.gov/study/NCT04036682
- Sponsor: Cullinan Therapeutics Inc.
- Phase: Phase 1/Phase 2
- Status: Active, not recruiting
- Drugs tested: zipalertinib
- Indication: previously treated EGFR exon 20 insertion-positive metastatic NSCLC
- Version: v1.0.0, edition 1
- Accepted: 2026-11-10 UTC
- Last checked: 2026-11-10 UTC
- Release hash: 772652623cff9443f83f7573b5933272615e5fe53e06e4dbe267264335d139ba

## Counts

- Commentary sources screened: 153
- Sources cited by verified statements: 58
- Verified statements: 129
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 58
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 31
- Speakers cited: 31
- Cited speakers with a verified identity: 26
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 21
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 21
- By role and specialty (the abstract's specialty counts):
  - 15 physician, Medical oncology
  - 5 physician, specialty not confirmed
  - 1 physician, Hematology and oncology
- Organisational or shared accounts (not counted as people): 13

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist described in the sources as presenting REZILIENT1 sees zipalertinib as a possible further treatment line because activity was observed after amivantamab, but notes lower response rates after amivantamab plus another exon20-targeting drug. Another speaker thinks one targeted therapy is probably enough. Comparative benefit remains unproven, and responses in patients with brain metastases do not establish CNS-specific benefit.

## Question clinicians left open

What evidence on overall survival and cross-resistance do clinicians say is needed to define zipalertinib’s place after amivantamab in previously treated EGFR exon 20 insertion-positive metastatic NSCLC, with or without prior exon 20–targeting TKI exposure?

From finding F1 (19 statements from 7 speakers in 10 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Speakers see a post-amivantamab sequencing opportunity; one account questions successive targeted therapies
  - 19 statements from 7 speakers in 10 sources, 3 of them podcasts or videos.
- F2. One interview stresses that noncomparative activity cannot establish the better treatment
  - 6 statements in 3 sources, 1 of them a podcast or video.
- F3. Speakers differ on zipalertinib response after pretreatment, discussing durability and safety; one cites CNS activity, another notes absent intracranial-response data and immature overall-survival data
  - 21 statements from 8 speakers in 17 sources, 2 of them podcasts or videos.
- F4. Speakers welcome possible CNS activity while emphasizing unresolved CNS-specific evidence
  - 16 statements from 6 speakers in 15 sources, 1 of them a podcast or video.
- F5. Speakers favor the safety profile; one interview challenges what “manageable” means
  - 26 statements from 5 speakers in 21 sources, 2 of them podcasts or videos.
- F6. Speakers want more oral options; one interview emphasizes time, cost and quality of life
  - 12 statements from 2 speakers in 7 sources, 2 of them podcasts or videos.
- F7. One case discussion makes access and biomarker status decisive for the next line
  - 7 statements from 2 speakers in 1 source.
- F8. One clinician asks about approval; nonclinical accounts describe a conditional regulatory path
  - 10 statements from 1 speaker in 9 sources, 1 of them a podcast or video.

The full report also has 2 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 19 | 11 | 10 | 7 | 4 |
| F2 | 6 | 4 | 3 | 0 | 3 |
| F3 | 21 | 18 | 17 | 8 | 3 |
| F4 | 16 | 17 | 15 | 6 | 4 |
| F5 | 26 | 25 | 21 | 5 | 4 |
| F6 | 12 | 9 | 7 | 2 | 3 |
| F7 | 7 | 7 | 1 | 2 | 3 |
| F8 | 10 | 9 | 9 | 1 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 12 | 3 | 0 | 0 | 4 | 19 | 3 | 6 posts and articles, 3 podcasts and video, 1 publication |
| F2 | 1 | 1 | 0 | 1 | 3 | 6 | 0 | 1 post or article, 1 podcast or video, 1 publication |
| F3 | 18 | 0 | 0 | 1 | 2 | 25 | 0 | 14 posts and articles, 2 podcasts and video, 1 publication |
| F4 | 7 | 1 | 0 | 0 | 8 | 19 | 4 | 13 posts and articles, 1 podcast or video, 1 publication |
| F5 | 12 | 1 | 0 | 3 | 10 | 29 | 4 | 17 posts and articles, 2 podcasts and video, 2 publications |
| F6 | 10 | 2 | 0 | 0 | 0 | 13 | 0 | 5 posts and articles, 2 podcasts and video |
| F7 | 3 | 1 | 2 | 0 | 1 | 7 | 0 | 1 post or article |
| F8 | 1 | 1 | 0 | 0 | 8 | 13 | 0 | 8 posts and articles, 1 podcast or video |

### Trial dimensions

- Primary endpoint: All Cohorts: The rate and severity of treatment emergent AEs.: F5 (9 shared claims)
- Primary endpoint: All Cohorts: The rate and severity of DLTs.: no finding draws on it directly
- Primary endpoint: Phase 2 Dose Expansion Cohorts: Overall response rate (ORR): F1 (1 shared claims), F2 (1 shared claims), F3 (9 shared claims), F4 (6 shared claims), F5 (2 shared claims)
- Primary endpoint: Module A: Pharmacokinetic (PK) parameter: no finding draws on it directly
- Primary endpoint: Module A: Pharmacokinetic (PK) parameter: no finding draws on it directly
- Primary endpoint: Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC): F1 (4 shared claims), F3 (7 shared claims), F4 (4 shared claims), F5 (2 shared claims), F6 (1 shared claims), F7 (1 shared claims), F8 (1 shared claims)
- Secondary endpoints: F1 (3 shared claims), F3 (7 shared claims), F4 (6 shared claims)
- Population and setting: F1 (4 shared claims), F2 (1 shared claims), F3 (5 shared claims), F4 (3 shared claims), F6 (2 shared claims)
- The comparison: F1 (1 shared claims), F2 (4 shared claims), F5 (2 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (1 shared claims), F3 (4 shared claims), F4 (1 shared claims), F5 (23 shared claims), F6 (2 shared claims)
- Design and conduct: F1 (4 shared claims), F2 (3 shared claims), F5 (1 shared claims)

## Abbreviations

- AE: adverse event
- CNS: central nervous system
- DLT: dose-limiting toxicity
- DOR: duration of response
- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- IRC: independent review committee
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- ORR: objective response rate
- TKI: tyrosine kinase inhibitor

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 129 | Paid |
| Who said each statement: the cited speakers | 31 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 21 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 26 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 20 | Free |
| Sources with links | 58 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 21 of the 31 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

17 discussed · 3 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: All Cohorts: The rate and severity of treatment emergent AEs. | discussed | 9 | 8 |
| Primary endpoint: All Cohorts: The rate and severity of DLTs. | no commentary found | 0 | 0 |
| Primary endpoint: Phase 2 Dose Expansion Cohorts: Overall response rate (ORR) | discussed | 18 | 15 |
| Primary endpoint: Module A: Pharmacokinetic (PK) parameter | no commentary found | 0 | 0 |
| Primary endpoint: Module A: Pharmacokinetic (PK) parameter | no commentary found | 0 | 0 |
| Primary endpoint: Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC) | discussed | 21 | 18 |
| Secondary endpoints | discussed | 12 | 11 |
| Population and setting | discussed | 18 | 13 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 6 | 4 |
| Safety and tolerability | discussed | 24 | 20 |
| Design and conduct | discussed | 10 | 7 |
| Post-amivantamab sequencing, cross-resistance and repeated targeted therapy | discussed | 19 | 14 |
| CNS activity, endpoint wording and applicability | discussed | 14 | 14 |
| Oral treatment, patient priorities and clinic burden | discussed | 11 | 6 |
| Post-amivantamab alternatives, access constraints and case burden | discussed | 7 | 1 |
| First-line combination versus later-line placement | discussed | 9 | 8 |
| Regulatory interest, submission milestones and possible label scope | discussed | 10 | 9 |
| Mechanistic explanations, selectivity and resistance questions | discussed | 6 | 5 |
| Perceived treatment progress and the distinction between clinical and organizational reactions | discussed | 17 | 14 |
| Earlier CLN-081 phase 1/2a evidence and dose interpretation | discussed | 23 | 8 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 28 statements · 22%** (from 4 videos · about 7 per source) | | | |
| YouTube | 28 | 4 | 4 |
| **Posts · 94 statements · 73%** (from 52 posts · about 2 per source) | | | |
| X threads | 91 | 50 | 130 |
| LinkedIn posts | 2 | 1 | 1 |
| Bluesky threads | 1 | 1 | 18 |
| **Primary sources · 7 statements · 5%** (cited for context, not screened · from 2 sources · about 4 per source) | | | |
| Publications (primary source, cited for context) | 7 | 2 | not screened |

- Screened window: 2021-06-08 to 2026-10-17
- Cited window: 2022-05-26 to 2026-10-17
- Retrieved: 2026-11-10

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
- Registry: NCT04036682 (https://clinicaltrials.gov/study/NCT04036682)
- Study IDs: CLN-081-001
- Sponsor: Cullinan Therapeutics Inc.
- Collaborators: Taiho Oncology, Inc.
- Design: Phase 1/Phase 2 · interventional, non randomized, sequential, phase1, phase2
- Status: Active, not recruiting
- Enrollment: 284 (estimated)
- Start: 2019-10-31 (actual)
- Primary completion: 2025-10-13 (actual)
- Primary endpoint: All Cohorts: The rate and severity of treatment emergent AEs. (24 months)
- Primary endpoint: All Cohorts: The rate and severity of DLTs. (24 months)
- Primary endpoint: Phase 2 Dose Expansion Cohorts: Overall response rate (ORR) (24 months)
- Primary endpoint: Module A: Pharmacokinetic (PK) parameter (24 months)
- Primary endpoint: Module A: Pharmacokinetic (PK) parameter (24 months)
- Primary endpoint: Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC) (24 months)
- Intervention: CLN-081 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- 193 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 31 sources about other trials or topics are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion. Unnamed trial references and alternative wording may be missing, and one identified X discussion was unavailable.
- Social posts, presentation relays, reposts, organizational coverage and investment-focused commentary are not independent HCP observations or a basis for measuring consensus.
- Some interview speech remains unidentified. Guest descriptions, author lists and professional profiles do not establish who spoke those passages.
- Clinical-role information is unavailable for several named authors. Identity or research associations do not increase the evidentiary weight of a view.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The early phase 1/2a data, early post-amivantamab Module C analysis and later publication use different populations and follow-up. Their estimates cannot be combined into a single result or trend.
- Some accounts contain unresolved endpoint labels, subgroup misassignments or internally inconsistent summaries. These remain attributed statements rather than corrected facts.
- Overall response among patients with brain metastases, intracranial response, CNS penetration and activity in unstable or symptomatic CNS disease are different questions.
- All-grade, high-grade, treatment-related and unspecified adverse-event percentages are not interchangeable. Subjective comparisons do not establish comparative safety.
- No exact regulatory label or standalone protocol document was available. Submission plans, NDA acceptance and target action dates do not establish approval or label breadth.
- No commentary specifically addressing Module A pharmacokinetic parameters or reported dose-limiting-toxicity rates was identified in the reviewed material.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-10 UTC: current edition
  - Routine maintenance: 1 fix (names, counts):
    - 2026-11-11 UTC: The count of statements from confirmed clinicians now follows the people cards.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-10 UTC. No changes.

## Offer

- Size: Focused · 129 verified statements · 58 from 21 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (26 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/rezilient1-nct04036682
- Agents: POST https://www.erudio.com/api/orders with {"report": "rezilient1-nct04036682", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=rezilient1-nct04036682

## Cite

Erudio Health. REZILIENT1 (NCT04036682): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 10, 2026. https://www.erudio.com/reports/rezilient1-nct04036682

## Machine access

- JSON: https://www.erudio.com/reports/rezilient1-nct04036682.json
- Markdown: https://www.erudio.com/reports/rezilient1-nct04036682.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/rezilient1-nct04036682/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "rezilient1-nct04036682"}`